AURX Stock Overview
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States.
Nuo Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.45|
|52 Week High||US$1.50|
|52 Week Low||US$0.0001|
|1 Month Change||-55.00%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||95.65%|
|5 Year Change||-27.42%|
|Change since IPO||-77.50%|
Recent News & Updates
|AURX||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how AURX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AURX performed against the US Market.
|AURX Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: Insufficient data to determine AURX's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine AURX's volatility change over the past year.
About the Company
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014.
Nuo Therapeutics Fundamentals Summary
|AURX fundamental statistics|
Is AURX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AURX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.031|
|Net Profit Margin||0.00%|
How did AURX perform over the long term?See historical performance and comparison
Is AURX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AURX?
Other financial metrics that can be useful for relative valuation.
|What is AURX's n/a Ratio?|
Price to Book Ratio vs Peers
How does AURX's PB Ratio compare to its peers?
|AURX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CRBP Corbus Pharmaceuticals Holdings
ALLR Allarity Therapeutics
INFI Infinity Pharmaceuticals
AURX Nuo Therapeutics
Price-To-Book vs Peers: AURX is expensive based on its Price-To-Book Ratio (35.1x) compared to the peer average (1.8x).
Price to Earnings Ratio vs Industry
How does AURX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: AURX is expensive based on its Price-To-Book Ratio (35.1x) compared to the US Biotechs industry average (1.5x)
Price to Book Ratio vs Fair Ratio
What is AURX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||35.1x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate AURX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AURX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AURX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AURX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AURX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Nuo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nuo Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Nuo Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Nuo Therapeutics's filings and announcements here.
How has Nuo Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AURX is currently unprofitable.
Growing Profit Margin: AURX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AURX is unprofitable, but has reduced losses over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare AURX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AURX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: AURX has a negative Return on Equity (-87.31%), as it is currently unprofitable.
Discover strong past performing companies
How is Nuo Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AURX's short term assets ($962.3K) exceed its short term liabilities ($475.7K).
Long Term Liabilities: AURX's short term assets ($962.3K) exceed its long term liabilities ($55.2K).
Debt to Equity History and Analysis
Debt Level: AURX is debt free.
Reducing Debt: AURX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AURX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AURX has less than a year of cash runway if free cash flow continues to grow at historical rates of 49.7% each year.
Discover healthy companies
What is Nuo Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AURX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AURX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AURX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AURX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AURX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Jorden (60 yo)
Mr. David E. Jorden, CPA has been the Chief Executive Officer and Chief Financial Officer of Nuo Therapeutics, Inc. since July 1, 2016. Mr. Jorden has been the Chief Executive Officer at Nanospectra Biosci...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: AURX's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: AURX's board of directors are seasoned and experienced ( 11.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AURX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.8%.
Nuo Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Nuo Therapeutics, Inc.
- Ticker: AURX
- Exchange: OTCPK
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$18.487m
- Shares outstanding: 41.08m
- Website: https://www.nuot.com
Number of Employees
- Nuo Therapeutics, Inc.
- 8285 El Rio
- Suite 190
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.